Kosuke Okuwaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kosuke Okuwaki has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Imaizumi
Department of Gastroenterology, Kitasato University School of Medicine, Minami, Sagamihara, Kanagawa, Japan
52 shared publicationsMitsuhiro Kida
Department of Gastroenterology, Kitasato University School of Medicine, Minami, Sagamihara, Kanagawa, Japan
51 shared publicationsTomohisa Iwai
Department of Gastroenterology Kitasato University School of Medicine Kanagawa Japan
47 shared publicationsWasaburo Koizumi
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
42 shared publicationsHiroshi Yamauchi
Department of Gastroenterology, Kitasato University School of Medicine, Japan
41 shared publications- Masafumi Watanabe
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan
29 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Balloon Occlusion of the Left Hepatic Duct to Facilitate Conversion to Endoscopic Ultrasound-Guided Hepaticogastrostomy
- 18 November 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Open AccessBalloon Occlusion of the Left Hepatic Duct to Facilitate Conversion to Endoscopic Ultrasound-Guided Hepaticogastrostomy
- Open Access
Evaluating a Modified American Society of Anesthesiologists Physical Status‐Based Sedation Management System for Pancreatobiliary Endoscopy: A Prospective Feasibility Study
Objectives: To prospectively evaluate the feasibility of implementing a modified American Society of Anesthesiologists Physical Status (ASA‐PS)‐based sedation management system for endoscopist‐managed sedation in pancreatobiliary endoscopy. Methods: This single‐center, single‐arm prospective feasibility study involved 2000 patients (2024–2025). Sedation risk was stratified using a modified ASA‐PS classification system combined with predefined high‐risk clinical factors (severe obesity, obstructive sleep apnea requiring continuous positive airway pressure, chronic obstructive pulmonary disease requiring home oxygen therapy, reduced functional capacity, and difficult sedation history). Patients meeting high‐risk criteria underwent pre‐procedural anesthesiologist assessment to determine sedation providers. The primary outcome was sedation‐related adverse event (SRAE) incidence during endoscopist‐managed sedation. The secondary outcomes were the sedation success rate and SRAE‐associated risk factors. Results: Among 2000 patients, 231 (11.6%) were classified as having high risk for sedation. Post‐assessment, anesthesiologists and endoscopists managed sedation for 86 (4.3%) and 1914 (95.7%) patients, respectively. In the endoscopist‐managed group, SRAEs occurred in 63 patients (3.3%), corresponding to a success rate of 96.7%. No patient required tracheal intubation or conversion to general anesthesia. In multivariable analysis, endoscopic ultrasonography‐guided sampling was independently associated with reduced SRAEs (odds ratio 0.407, 95% confidence interval 0.184–0.899; p = 0.026); no independent predictors of increased SRAEs were identified. Conclusions: The modified ASA‐PS‐based sedation management system may be a feasible approach in settings with limited anesthesiology resources, warranting further validation. Trial Registration: UMIN000053211
Open AccessEvaluating a Modified American Society of Anesthesiologists Physical Status‐Based Sedation Management System for Pancreatobiliary Endoscopy: A Prospective Feasibility Study
Objectives: To prospectively evaluate the feasibility of implementing a modified American Society of Anesthesiologists Physical Status (ASA‐PS)‐based sedation management system for endoscopist‐managed sedation in pancreatobiliary endoscopy. Methods: This single‐center, single‐arm prospective feasibility study involved 2000 patients (2024–2025). Sedation risk was stratified using a modified ASA‐PS classification system combined with predefined high‐risk clinical factors (severe obesity, obstructive sleep apnea requiring continuous positive airway pressure, chronic obstructive pulmonary disease requiring home oxygen therapy, reduced functional capacity, and difficult sedation history). Patients meeting high‐risk criteria underwent pre‐procedural anesthesiologist assessment to determine sedation providers. The primary outcome was sedation‐related adverse event (SRAE) incidence during endoscopist‐managed sedation. The secondary outcomes were the sedation success rate and SRAE‐associated risk factors. Results: Among 2000 patients, 231 (11.6%) were classified as having high risk for sedation. Post‐assessment, anesthesiologists and endoscopists managed sedation for 86 (4.3%) and 1914 (95.7%) patients, respectively. In the endoscopist‐managed group, SRAEs occurred in 63 patients (3.3%), corresponding to a success rate of 96.7%. No patient required tracheal intubation or conversion to general anesthesia. In multivariable analysis, endoscopic ultrasonography‐guided sampling was independently associated with reduced SRAEs (odds ratio 0.407, 95% confidence interval 0.184–0.899; p = 0.026); no independent predictors of increased SRAEs were identified. Conclusions: The modified ASA‐PS‐based sedation management system may be a feasible approach in settings with limited anesthesiology resources, warranting further validation. Trial Registration: UMIN000053211
- Open Access
- 30 September 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (5) , 857-858
Endoscopic ultrasound-guided cyanoacrylate injection for jejunal varices at the hepaticojejunostomy site using a forward-viewing echoendoscope
Endoscopic ultrasound-guided cyanoacrylate injection for jejunal varices at the hepaticojejunostomy site using a forward-viewing echoendoscope
- 30 September 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (5) , 857-858
Open AccessEndoscopic ultrasound-guided cyanoacrylate injection for jejunal varices at the hepaticojejunostomy site using a forward-viewing echoendoscope
Endoscopic ultrasound-guided cyanoacrylate injection for jejunal varices at the hepaticojejunostomy site using a forward-viewing echoendoscope
- 23 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (10) , 3262-3263
Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
- 23 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (10) , 3262-3263
Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
- Open Access
- 19 August 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Potential Utility of Endoscopic Ultrasonography Under Sedation with Remimazolam Plus Pethidine Hydrochloride
Endoscopic ultrasonography (EUS) requires sedation due to its strong discomfort. In recent years, the effectiveness of sedation using remimazolam as well as pethidine hydrochloride has been reported. However, the utility of sedation with remimazolam plus pethidine hydrochloride for EUS has not been determined. A total of 325 consecutive outpatient EUS cases performed between January and August 2025 were retrospectively reviewed. Statistical comparisons were performed using Fisher's exact test or the Mann–Whitney U test. Analyses were conducted using BellCurve for Excel, Version 4.08 (Social Survey Research Information Co., Ltd., Tokyo, Japan). A p-value <0.05 was considered statistically significant. Men accounted for 52.9% of the cohort, the median age was 71 years, and 67.1% had American Society of Anesthesiologists physical status of I. Pethidine hydrochloride (35 mg) was administered in all cases. The median initial dose of remimazolam was 2 mg (1–3 mg), and the median dose required until scope insertion was 3 mg (1–7 mg). The median EUS procedure time was 12 minutes. The median total remimazolam dose until EUS completion was 4 mg (1–15 mg). The procedure completion rate without rescue sedation was 96.6%. The median time from EUS procedure completion to patient exit from the endoscopy room was 44 minutes. There were 25 cases (7.7%) of sedation-related adverse events (AEs), with cardiorespiratory AEs occurring in 3.7% of cases. Outpatient EUS under sedation with remimazolam and pethidine hydrochloride achieved a high procedure completion rate and few cardiorespiratory AEs.
- 19 August 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Open AccessPotential Utility of Endoscopic Ultrasonography Under Sedation with Remimazolam Plus Pethidine Hydrochloride
Endoscopic ultrasonography (EUS) requires sedation due to its strong discomfort. In recent years, the effectiveness of sedation using remimazolam as well as pethidine hydrochloride has been reported. However, the utility of sedation with remimazolam plus pethidine hydrochloride for EUS has not been determined. A total of 325 consecutive outpatient EUS cases performed between January and August 2025 were retrospectively reviewed. Statistical comparisons were performed using Fisher's exact test or the Mann–Whitney U test. Analyses were conducted using BellCurve for Excel, Version 4.08 (Social Survey Research Information Co., Ltd., Tokyo, Japan). A p-value <0.05 was considered statistically significant. Men accounted for 52.9% of the cohort, the median age was 71 years, and 67.1% had American Society of Anesthesiologists physical status of I. Pethidine hydrochloride (35 mg) was administered in all cases. The median initial dose of remimazolam was 2 mg (1–3 mg), and the median dose required until scope insertion was 3 mg (1–7 mg). The median EUS procedure time was 12 minutes. The median total remimazolam dose until EUS completion was 4 mg (1–15 mg). The procedure completion rate without rescue sedation was 96.6%. The median time from EUS procedure completion to patient exit from the endoscopy room was 44 minutes. There were 25 cases (7.7%) of sedation-related adverse events (AEs), with cardiorespiratory AEs occurring in 3.7% of cases. Outpatient EUS under sedation with remimazolam and pethidine hydrochloride achieved a high procedure completion rate and few cardiorespiratory AEs.
- 4 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 3062-3063
Reply to “Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS‐Guided Versus Percutaneous Liver Biopsy”
- 4 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 3062-3063
Reply to “Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS‐Guided Versus Percutaneous Liver Biopsy”
- Open Access
- 16 July 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Incidence of Cholecystitis after Multihole Fully Covered Metal Stent Placement for Unresectable Malignant Distal Biliary Obstruction: A Prospective Exploratory Study
Cholecystitis and stent migration are adverse events of fully covered self-expandable metal stents (SEMS) for malignant distal biliary obstruction. The aim of this study was to evaluate the incidence of cholecystitis, clinical outcomes, and safety of a multihole fully covered SEMS (MHSEMS) in unresectable malignant distal biliary obstruction. This single-center, prospective, exploratory study included consecutive patients who underwent MHSEMS placement for unresectable malignant distal biliary obstruction between June 2023 and January 2024. The primary endpoint was the incidence of cholecystitis. Stent patency was analyzed using the Kaplan–Meier method, and categorical variables were expressed as percentages. Twenty patients were enrolled, and all were followed for up to 1 year or until death; technical and clinical success rates were both 100%. No cholecystitis occurred despite the presence of reported risk factors for cholecystitis: cholelithiasis or sludge (65%), contrast filling of the gallbladder (35%), and tumor involvement of the cystic duct (15%). Recurrent biliary obstruction occurred in six patients (30%): two stent migrations, three occlusions, and one biliary kinking. All recurrent biliary obstruction cases were managed endoscopically. Median time to recurrent biliary obstruction was not reached. One-year stent patency rate was 62%. Adverse events other than recurrent biliary obstruction were mild. No cholecystitis occurred after MHSEMS placement in this small prospective cohort, suggesting a favorable safety profile; however, larger comparative studies are needed to clarify its effect. UMIN000051182; registered June 1, 2023.
- 16 July 2026
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
Open AccessIncidence of Cholecystitis after Multihole Fully Covered Metal Stent Placement for Unresectable Malignant Distal Biliary Obstruction: A Prospective Exploratory Study
Cholecystitis and stent migration are adverse events of fully covered self-expandable metal stents (SEMS) for malignant distal biliary obstruction. The aim of this study was to evaluate the incidence of cholecystitis, clinical outcomes, and safety of a multihole fully covered SEMS (MHSEMS) in unresectable malignant distal biliary obstruction. This single-center, prospective, exploratory study included consecutive patients who underwent MHSEMS placement for unresectable malignant distal biliary obstruction between June 2023 and January 2024. The primary endpoint was the incidence of cholecystitis. Stent patency was analyzed using the Kaplan–Meier method, and categorical variables were expressed as percentages. Twenty patients were enrolled, and all were followed for up to 1 year or until death; technical and clinical success rates were both 100%. No cholecystitis occurred despite the presence of reported risk factors for cholecystitis: cholelithiasis or sludge (65%), contrast filling of the gallbladder (35%), and tumor involvement of the cystic duct (15%). Recurrent biliary obstruction occurred in six patients (30%): two stent migrations, three occlusions, and one biliary kinking. All recurrent biliary obstruction cases were managed endoscopically. Median time to recurrent biliary obstruction was not reached. One-year stent patency rate was 62%. Adverse events other than recurrent biliary obstruction were mild. No cholecystitis occurred after MHSEMS placement in this small prospective cohort, suggesting a favorable safety profile; however, larger comparative studies are needed to clarify its effect. UMIN000051182; registered June 1, 2023.
- Top Cited Papers
- 17 May 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
Randomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
Aim: To compare endoscopic ultrasound‐guided liver biopsy (EUS‐LB) with percutaneous liver biopsy (P‐LB) in terms of histological adequacy, safety, and patient‐reported pain in parenchymal liver disease. Methods: In this single‐center randomized controlled trial, 80 patients were assigned to either EUS‐LB ( n = 41) or P‐LB ( n = 39). The primary endpoint was histological adequacy, defined as total specimen length (TSL) ≥ 15 mm and ≥ 6 complete portal tracts (CPTs). The main secondary endpoints were the definitive histological diagnostic rate, specimen characteristics (CPTs, TSL, and longest specimen length), patient‐reported pain, and procedure‐related adverse events (AEs). EUS‐LB employed a 19‐gauge Franseen‐tip needle with wet suction under conscious sedation, whereas P‐LB used a 16‐gauge Tru‐Cut needle under local anesthesia. Results: Histological adequacy based on predefined histologic criteria was achieved more frequently with EUS‐LB than with P‐LB (70.7% vs. 10.3%; difference, 60.4%; 95% CI 43.5–77.3). The definitive histological diagnostic rates were similar (92.7% vs. 97.4%). The median TSL was longer with EUS‐LB (20.0 vs. 12.8 mm), whereas ≥ 6 CPTs were more common with P‐LB (97.4% vs. 80.5%). AEs occurred in 2.4% versus 25.6%, driven in the P‐LB arm by procedural stress–related hemodynamic responses (transient grade III hypertension); patient‐reported pain favored EUS‐LB (no pain during the procedure, 95.1% vs. 30.8%). No serious AEs or bleeding events occurred, and none required prolonged hospitalization. Conclusions: EUS‐LB met the noninferiority criterion for histologic adequacy and achieved a diagnostic performance comparable to that of P‐LB with lower patient‐reported pain. EUS‐LB may be a reasonable alternative when endoscopic expertise and sedation are available.
- 17 May 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
Top Cited PapersRandomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
Aim: To compare endoscopic ultrasound‐guided liver biopsy (EUS‐LB) with percutaneous liver biopsy (P‐LB) in terms of histological adequacy, safety, and patient‐reported pain in parenchymal liver disease. Methods: In this single‐center randomized controlled trial, 80 patients were assigned to either EUS‐LB ( n = 41) or P‐LB ( n = 39). The primary endpoint was histological adequacy, defined as total specimen length (TSL) ≥ 15 mm and ≥ 6 complete portal tracts (CPTs). The main secondary endpoints were the definitive histological diagnostic rate, specimen characteristics (CPTs, TSL, and longest specimen length), patient‐reported pain, and procedure‐related adverse events (AEs). EUS‐LB employed a 19‐gauge Franseen‐tip needle with wet suction under conscious sedation, whereas P‐LB used a 16‐gauge Tru‐Cut needle under local anesthesia. Results: Histological adequacy based on predefined histologic criteria was achieved more frequently with EUS‐LB than with P‐LB (70.7% vs. 10.3%; difference, 60.4%; 95% CI 43.5–77.3). The definitive histological diagnostic rates were similar (92.7% vs. 97.4%). The median TSL was longer with EUS‐LB (20.0 vs. 12.8 mm), whereas ≥ 6 CPTs were more common with P‐LB (97.4% vs. 80.5%). AEs occurred in 2.4% versus 25.6%, driven in the P‐LB arm by procedural stress–related hemodynamic responses (transient grade III hypertension); patient‐reported pain favored EUS‐LB (no pain during the procedure, 95.1% vs. 30.8%). No serious AEs or bleeding events occurred, and none required prolonged hospitalization. Conclusions: EUS‐LB met the noninferiority criterion for histologic adequacy and achieved a diagnostic performance comparable to that of P‐LB with lower patient‐reported pain. EUS‐LB may be a reasonable alternative when endoscopic expertise and sedation are available.
- Open Access
- 30 March 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (2) , 273-279
Feasibility of primary precut sphincterotomy in endoscopic retrograde cholangiopancreatography for patients with large oral protrusions of the duodenal papilla; prospective observation study in Japan
Background/Aims: Large oral protrusions may increase the difficulty of biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP) and often require precut sphincterotomy. Precut sphincterotomy is a risk factor for post-ERCP pancreatitis (PEP). However, this may be reduced by a primary precut sphincterotomy. This study aimed to evaluate the results of biliary cannulation after primary precut sphincterotomy in patients with large oral protrusions identified during ERCP.Methods: In this prospective observation study, we included 38 patients with naïve papillae who underwent ERCPs between January 2021 and December 2022 that revealed large oral protrusions and who underwent primary precut sphincterotomies as the biliary cannulation method. Primary precut sphincterotomy was performed by an experienced endoscopist in all cases.Results: The biliary cannulation success rate for primary precut sphincterotomies was 100% (38/38 patients). There were seven cases (18.4%) of ERCP-related adverse events, specifically bleeding. Of these, six (15.8%) were mild and one (2.6%) was moderate. No cases of PEP were observed.Conclusions: Primary precut sphincterotomy for large oral protrusions performed by an experienced endoscopist had a high biliary cannulation success rate without the occurrence of PEP. This procedure can be used for biliary cannulation in patients with large oral protrusions (University Hospital Medical Information Network-Clinical Trials Registry number: UMIN000042805).
- 30 March 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (2) , 273-279
Open AccessFeasibility of primary precut sphincterotomy in endoscopic retrograde cholangiopancreatography for patients with large oral protrusions of the duodenal papilla; prospective observation study in Japan
Background/Aims: Large oral protrusions may increase the difficulty of biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP) and often require precut sphincterotomy. Precut sphincterotomy is a risk factor for post-ERCP pancreatitis (PEP). However, this may be reduced by a primary precut sphincterotomy. This study aimed to evaluate the results of biliary cannulation after primary precut sphincterotomy in patients with large oral protrusions identified during ERCP.Methods: In this prospective observation study, we included 38 patients with naïve papillae who underwent ERCPs between January 2021 and December 2022 that revealed large oral protrusions and who underwent primary precut sphincterotomies as the biliary cannulation method. Primary precut sphincterotomy was performed by an experienced endoscopist in all cases.Results: The biliary cannulation success rate for primary precut sphincterotomies was 100% (38/38 patients). There were seven cases (18.4%) of ERCP-related adverse events, specifically bleeding. Of these, six (15.8%) were mild and one (2.6%) was moderate. No cases of PEP were observed.Conclusions: Primary precut sphincterotomy for large oral protrusions performed by an experienced endoscopist had a high biliary cannulation success rate without the occurrence of PEP. This procedure can be used for biliary cannulation in patients with large oral protrusions (University Hospital Medical Information Network-Clinical Trials Registry number: UMIN000042805).
- 21 January 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (4) , 401-409
Depth-oriented organ-preserving salvage endoscopic strategy with argon plasma coagulation and photodynamic therapy for residual or recurrent esophageal squamous cell carcinoma after chemoradiotherapy
Background: Residual or recurrent esophageal squamous cell carcinoma (ESCC) after definitive chemoradiotherapy (CRT) is a therapeutic challenge. Salvage surgery is invasive, and endoscopic resection is limited by radiation-induced fibrosis. Argon plasma coagulation (APC) and photodynamic therapy (PDT) are less invasive salvage options, however their role in depth-oriented organ-preserving strategies remains unclear. Methods: We analyzed 52 consecutive patients with residual or recurrent ycT1–2 ESCC who underwent CRT. APC is indicated for ycT1a lesions, and PDT is indicated for ycT1b–T2 lesions, with flexibility. We evaluated the survival rates, adverse events, and predictors of local failure. Results: Thirteen patients underwent APC, and 39 underwent PDT. The overall local complete response rate was 78.8% (92.3% APC and 74.3% PDT). During a median follow-up of 24.7 months (range, 1.9–110.5 months), the 2-year overall survival, progression-free survival, disease-specific survival, and esophagectomy-free survival rates were 82.8%, 44.0%, 86.7%, and 75.9%, respectively. Adverse events occurred in 30.8% of APC patients and 41.0% of PDT patients, all of which were manageable without treatment-related mortality. Multivariate analysis identified ycT2 stage (hazard ratio [HR]: 9.61, 95% confidence interval [CI]: 1.04–88.55, P = .04) and tumor location in the upper thoracic esophagus (HR 3.48, 95% CI 1.02–11.85; P = .04) as independent predictors of local failure. Conclusions: A salvage endoscopic strategy applying APC for ycT1a and PDT for ycT1b–T2, with flexibility based on tumor depth, is feasible, safe, and effective. Tailoring treatment to invasion depth may optimize organ preservation and local control in residual or recurrent ESCC after CRT.
- 21 January 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (4) , 401-409
Depth-oriented organ-preserving salvage endoscopic strategy with argon plasma coagulation and photodynamic therapy for residual or recurrent esophageal squamous cell carcinoma after chemoradiotherapy
Background: Residual or recurrent esophageal squamous cell carcinoma (ESCC) after definitive chemoradiotherapy (CRT) is a therapeutic challenge. Salvage surgery is invasive, and endoscopic resection is limited by radiation-induced fibrosis. Argon plasma coagulation (APC) and photodynamic therapy (PDT) are less invasive salvage options, however their role in depth-oriented organ-preserving strategies remains unclear. Methods: We analyzed 52 consecutive patients with residual or recurrent ycT1–2 ESCC who underwent CRT. APC is indicated for ycT1a lesions, and PDT is indicated for ycT1b–T2 lesions, with flexibility. We evaluated the survival rates, adverse events, and predictors of local failure. Results: Thirteen patients underwent APC, and 39 underwent PDT. The overall local complete response rate was 78.8% (92.3% APC and 74.3% PDT). During a median follow-up of 24.7 months (range, 1.9–110.5 months), the 2-year overall survival, progression-free survival, disease-specific survival, and esophagectomy-free survival rates were 82.8%, 44.0%, 86.7%, and 75.9%, respectively. Adverse events occurred in 30.8% of APC patients and 41.0% of PDT patients, all of which were manageable without treatment-related mortality. Multivariate analysis identified ycT2 stage (hazard ratio [HR]: 9.61, 95% confidence interval [CI]: 1.04–88.55, P = .04) and tumor location in the upper thoracic esophagus (HR 3.48, 95% CI 1.02–11.85; P = .04) as independent predictors of local failure. Conclusions: A salvage endoscopic strategy applying APC for ycT1a and PDT for ycT1b–T2, with flexibility based on tumor depth, is feasible, safe, and effective. Tailoring treatment to invasion depth may optimize organ preservation and local control in residual or recurrent ESCC after CRT.